tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Nuvectis Pharma provides final clinical data update from NXP800 Phase 1b study

Nuvectis Pharma (NVCT) provided the final clinical data update from the Phase 1b study of NXP800 in recurrent, platinum resistant, ARID1a-mutated ovarian cancer and reported on the progress towards the initiation of the Phase 1b program for NXP900. As part of the NXP800 Phase 1b study, 17 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer were treated with NXP800 at the target dose of 75 mg/day, administered intermittently or daily, with data available for 13 patients. Overall, treatment resulted in 2 patients achieving partial response and 3 achieving stable disease. Thrombocytopenia, a key toxicity identified early in the study, was successfully managed following the switch to intermittent dosing. The company will not pursue further development of NXP800 in ovarian cancer but, in the coming months, will evaluate the feasibility of development opportunities for NXP800 in other cancer types, such as endometrial and prostate cancers, in which the patients’ performance status and other characteristics may allow treatment with NXP800 to be more impactful. With the recent completion of the NXP900 DDI study, which supports the potential combination of NXP900 with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors in non-small cell lung cancer, and now the completion of the Phase 1a dose-escalation study, the Company is poised for the start of the Phase 1b study of NXP900, expected in the coming weeks. The Phase 1a dose escalation study evaluated the safety, pharmacokinetics and pharmacodynamics of NXP900 in patients with advanced solid tumors. In this study, a dose range of 20 to 300 mg/day was evaluated and the dose limiting toxicity dose level was not reached. As presented by the study investigators at the 2025 American Association for Cancer Research conference, the most common treatment emergent adverse events were mainly gastrointestinal-related and mild to moderate in intensity; systemic exposure to NXP900 increased with increased doses and a robust pharmacodynamic response of approximately 90% inhibition of SRC kinase phosphorylation was elicited at doses of 150 mg/day and higher, suggesting a potentially wide therapeutic window. The final data from the study is expected to be presented at a future medical/scientific conference.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1